AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35353229 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of family breakfast
Number of subjects: 1964
Study 35353263 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission (ASDAS-CRP)
Number of subjects: 969
Study 35353263 — intervention group
Group type: EXPERIMENTAL
Intervention: Low disease activity (ASDAS-CRP)
Number of subjects: 969
Study 35353263 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug switching
Number of subjects: 969
Study 35353263 — intervention group
Group type: EXPERIMENTAL
Intervention: MASES and BASMI scores in drug switchers
Number of subjects: 969
Study 35353962 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine at a total dose of 7.0 mg per kilogram
Number of subjects: 254
Study 35354274 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab, dosage not specified, duration not specified
Number of subjects: 0
Study 35354298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioembolism
Number of subjects: 1015
Study 35354298 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy passes in cardioembolism patients
Number of subjects: 1015
Study 35354310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel-based autologous chondrocyte implantation (ACI)
Number of subjects: 100
Study 35354442 — intervention group
Group type: EXPERIMENTAL
Intervention: PLUSS model implementation
Number of subjects: 130
Study 35354442 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental training
Number of subjects: 130
Study 35354442 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for preschool professionals
Number of subjects: 130
Study 35354442 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening procedure
Number of subjects: 130
Study 35354442 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-related outcomes
Number of subjects: 130
Study 35354445 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive menstrual health and hygiene (MHH) intervention integrated within community-based sexual and reproductive health (SRH) service
Number of subjects: 9
Study 35354456 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies for PrEP integration into family planning services
Number of subjects: 1000
Study 35354456 — intervention group
Group type: EXPERIMENTAL
Intervention: Private, youth-friendly clinic
Number of subjects: 1000
Study 35354456 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoption of PrEP delivery among non-study staff
Number of subjects: 1000
Study 35354456 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for FP providers
Number of subjects: 1000
Study 35354482 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 20 cmH2O
Number of subjects: 38
Study 35354482 — intervention group
Group type: COMPARATOR
Intervention: Passive leg raise maneuver
Number of subjects: 38
Study 35354561 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision Impairment in Low Luminance (VILL-33) questionnaire
Number of subjects: 716
Study 35354561 — intervention group
Group type: COMPARATOR
Intervention: Advanced AMD stage
Number of subjects: 716
Study 35354581 — intervention group
Group type: EXPERIMENTAL
Intervention: HTN+/T2D+
Number of subjects: 0
Study 35354581 — intervention group
Group type: EXPERIMENTAL
Intervention: HTN+/T2D-
Number of subjects: 0
Study 35354581 — intervention group
Group type: COMPARATOR
Intervention: HTN-/T2D-
Number of subjects: 0
Study 35354581 — intervention group
Group type: COMPARATOR
Intervention: ADNI non-Hispanic White participants
Number of subjects: 0
Study 35354581 — intervention group
Group type: COMPARATOR
Intervention: ADNI + NACC Hispanic cohort
Number of subjects: 0
Study 35354626 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool FIT plus urine VOC
Number of subjects: 1915
Study 35354626 — intervention group
Group type: COMPARATOR
Intervention: Stool FIT alone
Number of subjects: 1915
Study 35354626 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation of FIT + VOC
Number of subjects: 1915
Study 35354640 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative nursing care intervention through Participatory Action Research activities
Number of subjects: 0
Study 35354640 — intervention group
Group type: COMPARATOR
Intervention: Usual care dynamics
Number of subjects: 0
Study 35354660 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE risk score
Number of subjects: 5015
Study 35354660 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal guideline-recommended care
Number of subjects: 5015
Study 35354660 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-risk patients
Number of subjects: 5015
Study 35354660 — intervention group
Group type: COMPARATOR
Intervention: High-risk patients
Number of subjects: 5015
Study 35354659 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA in South Asian patients
Number of subjects: 170
Study 35354659 — intervention group
Group type: COMPARATOR
Intervention: CCTA in Caribbean black patients
Number of subjects: 170
Study 35354808 — intervention group
Group type: EXPERIMENTAL
Intervention: Devimistat in combination with high dose cytarabine and mitoxantrone
Number of subjects: 48
Study 35354808 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance devimistat
Number of subjects: 48
Study 35354808 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned post-hoc analysis
Number of subjects: 48
Study 35354808 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA sequencing data
Number of subjects: 48
Study 35354808 — intervention group
Group type: EXPERIMENTAL
Intervention: Devimistat
Number of subjects: 48
Study 35354808 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological or genetic inhibition of mitochondrial fission or autophagy
Number of subjects: 48
Study 35355147 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA) during CRRT
Number of subjects: 11
Study 35355397 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalassaemia patients (TDT and TIT)
Number of subjects: 137
Study 35355397 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalassaemia patients (TIT)
Number of subjects: 137
Study 35355397 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalassaemia presence (TDT or TIT)
Number of subjects: 137
Study 35355397 — intervention group
Group type: COMPARATOR
Intervention: Matched cohort with no history of thalassaemia
Number of subjects: 137
Study 35355438 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP) induction chemotherapy
Number of subjects: 0
Study 35355447 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat (6-mg single dose)
Number of subjects: 0
Study 35355714 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (medium-high doses)
Number of subjects: 28
Study 35355964 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with myocardial damage
Number of subjects: 19
Study 35355991 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of melatonin and DADA (diisopropylamine dichloroacetate)
Number of subjects: 0
Study 35355991 — intervention group
Group type: COMPARATOR
Intervention: Melatonin alone
Number of subjects: 0
Study 35355991 — intervention group
Group type: COMPARATOR
Intervention: DADA alone
Number of subjects: 0
Study 35355991 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of melatonin and DADA
Number of subjects: 0
Study 35356149 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy balance modeling displayed on weight graphs combined with a wrist-worn bite counting sensor
Number of subjects: 0
Study 35356149 — intervention group
Group type: COMPARATOR
Intervention: Traditional online behavioral weight loss program
Number of subjects: 0
Study 35356197 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-CAR T cell therapy (tisagenlecleucel or on an institutional clinical trial)
Number of subjects: 38
Study 35356225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary branch of vagus nerve preservation group (Group A)
Number of subjects: 158
Study 35356225 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical treatment group (Group B)
Number of subjects: 158
Study 35356225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study 35356262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib-based therapy
Number of subjects: 76
Study 35356508 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 5 mg/day
Number of subjects: 39
Study 35356508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 35356551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 35356551 — intervention group
Group type: COMPARATOR
Intervention: Standard parametric models
Number of subjects: 0
Study 35356551 — intervention group
Group type: COMPARATOR
Intervention: Piecewise and cubic spline models
Number of subjects: 0
Study 35356551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture cure, parametric mixture, and landmark response models
Number of subjects: 0
Study 35356713 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 737
Study 35356726 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental infant formula (EF) enriched with milk fat globule membrane (MFGM), long-chain polyunsaturated fatty acids (LC-PUFAs), and synbiotics
Number of subjects: 108
Study 35356726 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental infant formula (EF)
Number of subjects: 108
Study 35356726 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula (SF)
Number of subjects: 108
Study 35356726 — intervention group
Group type: COMPARATOR
Intervention: Breastfed (BF)
Number of subjects: 108
Study 35356974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer stem cells (CSCs) frequency
Number of subjects: 35
Study 35356974 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CSC frequency in locally advanced disease
Number of subjects: 35
Study 35356974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower CSC frequency in early-stage patients
Number of subjects: 35
Study 35357027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (1, 3 or 10 mg/kg)
Number of subjects: 546
Study 35357027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Number of subjects: 546
Study 35357219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) with Implantable Defibrillator
Number of subjects: 0
Study 35357219 — intervention group
Group type: COMPARATOR
Intervention: Cardiac Resynchronization Therapy (CRT) without Implantable Defibrillator
Number of subjects: 0
Study 35357290 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton radiation with FLASH RT adaptation
Number of subjects: 0
Study 35357290 — intervention group
Group type: EXPERIMENTAL
Intervention: α-particle radiation therapies including brachytherapy, proton-boron capture therapy (PBCT), and boron-neutron capture therapy (BNCT)
Number of subjects: 0
Study 35357290 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion therapy
Number of subjects: 0
Study 35357290 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinatorial immune-based therapies with high-LET RT
Number of subjects: 0
Study 35357325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness mobile application (Headspace) used daily for 30 days (up to 10 minutes a day)
Number of subjects: 140
Study 35357325 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 140
Study 35357436 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial compaction (measured as percentage difference in endometrial thickness between T1 and T2)
Number of subjects: 186
Study 35357436 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial compaction >0%
Number of subjects: 186
Study 35357436 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial compaction ≥5%
Number of subjects: 186
Study 35357436 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial compaction ≥10%
Number of subjects: 186
Study 35357436 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial compaction ≥15%
Number of subjects: 186
Study 35357436 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial compaction ≥20%
Number of subjects: 186
Study 35357436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-analysis by FET protocol type (programmed vs modified natural)
Number of subjects: 186
Study 35357767 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV pre-exposure prophylaxis (PrEP)
Number of subjects: 599
Study 35357767 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-positive participants
Number of subjects: 599
Study 35357767 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-negative participants
Number of subjects: 599
Study 35357767 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PrEP adopters
Number of subjects: 599
Study 35357903 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with cisplatin during optimal cytoreductive surgery (CRS)
Number of subjects: 35
Study 35358290 — intervention group
Group type: EXPERIMENTAL
Intervention: Leronlimab (350 mg or 700 mg)
Number of subjects: 9
Study 35358290 — intervention group
Group type: EXPERIMENTAL
Intervention: Leronlimab (50 mg/kg)
Number of subjects: 9
Study 35358443 — intervention group
Group type: EXPERIMENTAL
Intervention: Index therapies included immunochemotherapy (n=133)
Number of subjects: 441
Study 35358443 — intervention group
Group type: EXPERIMENTAL
Intervention: Index therapies included anti-CD20 antibody monotherapy (n=53)
Number of subjects: 441
Study 35358443 — intervention group
Group type: EXPERIMENTAL
Intervention: Index therapies included lenalidomide with or without anti-CD20 (n=37)
Number of subjects: 441
Study 35358443 — intervention group
Group type: EXPERIMENTAL
Intervention: Index therapies included phosphoinositide 3-kinase inhibitors with or without anti-CD20 (n=25)
Number of subjects: 441
Study 35358442 — intervention group
Group type: EXPERIMENTAL
Intervention: FMA reduced-intensity conditioned HSCT
Number of subjects: 249
Study 35358810 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline phenotypic measurements (e.g., patient global estimate of health status, 6-min walk distance, HRQoL measures)
Number of subjects: 0
Study 35358810 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk distance cutoff
Number of subjects: 0
Study 35358810 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQoL measure cutoffs
Number of subjects: 0
Study 35358904 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisocytosis (RDW > 14.5) in Cohort 1
Number of subjects: 360
Study 35358904 — intervention group
Group type: EXPERIMENTAL
Intervention: RDW in Cohort 1
Number of subjects: 360
Study 35358904 — intervention group
Group type: EXPERIMENTAL
Intervention: RDW in Cohort 2
Number of subjects: 360
Study 35358904 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisocytosis and myocardial fibrosis in both cohorts
Number of subjects: 360
Study 35358904 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated RDW in both cohorts
Number of subjects: 360
Study 35358998 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated tumor cells (10-gene signature)
Number of subjects: 34
Study 35358998 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of T-cell inflamed microenvironment in LN
Number of subjects: 34
Study 35358998 — intervention group
Group type: COMPARATOR
Intervention: Clonal evolution
Number of subjects: 34
Study 35358998 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing (scRNA-seq)
Number of subjects: 34
Study 35358998 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA velocity analysis
Number of subjects: 34
Study 35358998 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES)
Number of subjects: 34
Study 35359000 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (atezo) with obinutuzumab (G) and bendamustine
Number of subjects: 40
Study 35359139 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative perfusion index (PI)
Number of subjects: 95
Study 35359139 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative plethysmographic variability index (PVI)
Number of subjects: 95
Study 35359139 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline dicrotic plethysmography (Dicpleth)
Number of subjects: 95
Study 35359899 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (IMP) - Molecular radiotherapy (details on dosage and duration not available)
Number of subjects: 0
Study 35360218 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP-directed treatment
Number of subjects: 68
Study 35360218 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients treated at another ward)
Number of subjects: 68
Study 35360224 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic Regulation Therapy (ART) using chronic vagus nerve stimulation (VNS)
Number of subjects: 15
Study 35360431 — intervention group
Group type: EXPERIMENTAL
Intervention: ICTP block (T2 TPVB supplemented with IC block)
Number of subjects: 80
Study 35360431 — intervention group
Group type: COMPARATOR
Intervention: IC block (combined interscalene brachial plexus with superficial cervical plexus block)
Number of subjects: 80
Study 35360431 — intervention group
Group type: EXPERIMENTAL
Intervention: ICTP block
Number of subjects: 80
Study 35360431 — intervention group
Group type: COMPARATOR
Intervention: IC block
Number of subjects: 80
Study 35360431 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (rescue anesthesia)
Number of subjects: 80
Study 35360522 — intervention group
Group type: EXPERIMENTAL
Intervention: R3-AFP score including last available pre-LT AFP value
Number of subjects: 2444
Study 35360522 — intervention group
Group type: COMPARATOR
Intervention: R3 model without AFP
Number of subjects: 2444
Study 35360736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha variant (B.1.1.7)
Number of subjects: 333
Study 35360736 — intervention group
Group type: COMPARATOR
Intervention: Beta variant (B.1.351)
Number of subjects: 333
Study 35360744 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescents
Number of subjects: 0
Study 35360928 — intervention group
Group type: EXPERIMENTAL
Intervention: ANA catheter system combined with stent retriever
Number of subjects: 74
Study 35360980 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb difference (including thumb hypoplasia)
Number of subjects: 48
Study 35360980 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral upper limb differences
Number of subjects: 48
Study 35360980 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 48
Study 35360980 — intervention group
Group type: EXPERIMENTAL
Intervention: Late diagnosis of limb anomalies
Number of subjects: 48
Study 35360980 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for FA
Number of subjects: 48
Study 35361107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular tachyarrhythmias (VTA) due to coronary artery disease (CAD) requiring percutaneous coronary intervention (PCI) in young adults.
Number of subjects: 259
Study 35361107 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic VTA in young adults.
Number of subjects: 259
Study 35361107 — intervention group
Group type: EXPERIMENTAL
Intervention: VTA associated with underlying channelopathies in young adults.
Number of subjects: 259
Study 35361107 — intervention group
Group type: EXPERIMENTAL
Intervention: VTA associated with primary cardiomyopathies in young adults.
Number of subjects: 259
Study 35361107 — intervention group
Group type: EXPERIMENTAL
Intervention: VTA associated with acute myocardial infarction (AMI) in young adults.
Number of subjects: 259
Study 35361107 — intervention group
Group type: COMPARATOR
Intervention: VTA associated with acute myocardial infarction (AMI) in adults.
Number of subjects: 259
Study 35361107 — intervention group
Group type: COMPARATOR
Intervention: Idiopathic VTA in adults.
Number of subjects: 259
Study 35361107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation (CPR) in all patients.
Number of subjects: 259
Study 35361107 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF) < 35% in young adults.
Number of subjects: 259
Study 35361107 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality in young adults and adults.
Number of subjects: 259
Study 35361107 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rates at index hospitalization and after 2.5 years for young adults and adults.
Number of subjects: 259
Study 35361185 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy aimed at stabilizing the hip joint
Number of subjects: 0
Study 35361185 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic plication of the hip joint capsule
Number of subjects: 0
Study 35361224 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted classification criteria for migraine and CH
Number of subjects: 18
Study 35361224 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict application of ICHD-3 criteria
Number of subjects: 18
Study 35361224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignoring episodic TTH classifications
Number of subjects: 18
Study 35361224 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-based system for headache trigger detection
Number of subjects: 18
Study 35361350 — intervention group
Group type: COMPARATOR
Intervention: Stage I (normal renal function)
Number of subjects: 10354
Study 35361350 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III (moderate dysfunction)
Number of subjects: 10354
Study 35361350 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 10354
Study 35361350 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 10354
Study 35361478 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) concentration
Number of subjects: 978
Study 35361478 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient boosting model for detection of CAD
Number of subjects: 978
Study 35361487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg administered intravenously Q3W for up to 35 cycles (approximately 2 years)
Number of subjects: 101
Study 35361490 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartPilot® View (SPV)
Number of subjects: 493
Study 35361490 — intervention group
Group type: COMPARATOR
Intervention: Control (CONTROL)
Number of subjects: 493
Study 35361684 — intervention group
Group type: EXPERIMENTAL
Intervention: AIEC identification within the neoterminal ileum at M6
Number of subjects: 181